Form 4: Bicycle Therapeutics Director Receives Equity Grants

Bicycle Therapeutics PLC director Janice Bourque was granted 9,500 restricted share units and options to purchase 19,000 ordinary shares.

Summary

• Janice Bourque, a Director at Bicycle Therapeutics PLC, was granted 9,500 Restricted Share Units (RSUs) and stock options to purchase 19,000 ordinary shares.
• The RSUs represent a contingent right to receive one ordinary share each and were granted on January 2, 2026, with a price of $0.
• The stock options, granted on January 2, 2026, have an exercise price of $7.08 per share and an expiration date of January 2, 2036.
• Both the RSU award and the stock options will vest in four equal installments on March 15, 2026, June 15, 2026, September 15, 2026, and December 15, 2026.
• Following these transactions, Janice Bourque beneficially owns 32,500 ordinary shares and 19,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The filing reports routine equity compensation for a director, which is a neutral to slightly positive event as it aligns management interests with shareholders. It does not contain any significant positive or negative operational or financial news.

Positives

• The equity grants align the director's interests with those of shareholders, incentivizing long-term performance.
• The grants represent a form of compensation and retention for a key board member.

Risks

• Potential for minor shareholder dilution upon the vesting and exercise of the granted equity.

Future Outlook

The granted RSUs and stock options are subject to a vesting schedule, with shares becoming fully vested by December 15, 2026, indicating a future commitment and incentive structure for the director. The stock options have a long-term expiration date of January 2, 2036.

Industry Context

Equity compensation, including Restricted Share Units and stock options, is a standard practice in the biotechnology and pharmaceutical industries to attract, retain, and incentivize directors and executives. These grants align the interests of company leadership with long-term shareholder value creation.

Comparison to Industry Standards

• The use of RSUs and stock options for director compensation is a common practice across publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• The vesting schedule over approximately one year is typical for director grants, aiming to retain talent and align interests over a reasonable period.
• The exercise price of $7.08 for the stock options would typically be set at or above the market price on the grant date, which is standard for incentive options.

Related Party Transactions

• The equity grants to a director could be considered a related party transaction, as it involves compensation to an insider.

Stakeholder Impact

• Shareholders: Minor potential for dilution upon vesting and exercise of the equity, but also improved alignment of director incentives with shareholder value.

Next Steps

• Vesting of 2,375 RSUs on March 15, 2026.
• Vesting of 4,750 stock options on March 15, 2026.
• Subsequent quarterly vesting installments for both RSUs and stock options on June 15, 2026, September 15, 2026, and December 15, 2026.

Key Dates

Recommendation

This Form 4 filing reports a routine equity compensation grant to a director. While it aligns the director's interests with shareholders, it does not provide new fundamental information about the company's operations, financial performance, or strategic direction that would warrant a change in investment recommendation. It is a standard disclosure of an insider transaction.

Keywords

Bicycle Therapeutics, BCYC, Form 4, Insider Transaction, Restricted Share Units, RSU, Stock Options, Equity Compensation, Director Compensation, Janice Bourque